Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 33.3% during trading on Friday . The stock traded as high as C$0.11 and last traded at C$0.10. 1,288,111 shares changed hands during mid-day trading, an increase of 236% from the average session volume of 383,414 shares. The stock had previously closed at C$0.08.
Hemostemix Stock Performance
The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The firm has a market capitalization of C$19.58 million, a PE ratio of -2.97 and a beta of 1.39. The stock’s 50 day moving average price is C$0.11 and its two-hundred day moving average price is C$0.12.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- How Can Investors Benefit From After-Hours Trading
- DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?
- Differences Between Momentum Investing and Long Term Investing
- Engines to AI: Cummins’ Surprising Growth Driver
- How to Profit From Value Investing
- Smaller Industrials Names Seeing Surging Growth: Here’s Why
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
